
    
      The primary objective is to assess the efficacy of nal-IRI in gemcitabine pre-treated
      patients with advanced, unresectable and metastatic cholangio- and gallbladder carcinoma
      eligible for treatments after failure to respond to a gemcitabine-based treatment
    
  